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Serious cardiac toxicity following ropivacaine infusion is rare. Side effects that responded to lipid infusions have been described [1] .
A 57-year-old man with impaired liver function and end-stage renal disease (ESRD) was admitted for an belowknee amputation. Postoperatively, ropivacaine catheters were placed.
Later, the patient became lethargic, and bradycardic, with tinnitus, dysgeusia, and hallucinations. EKG showed widened QRS and prolonged QT without ST changes (Supplementary Figure 1a, b) . Echocardiography revealed an ejection fraction (EF) of 20 % without wall motion abnormality. Peak troponin-I-ES = 4.3. We estimated the infusion to be 1,540 mg ropivacaine.
A total of 2,480 ml intralipids 20 %, and one round of plasmapheresis, were given with transient response. The patient ultimately died of cardiac arrest (Supplementary Table 1.) Cardiac toxicity has been reversed using infusion of lipids in animal models. Reports have suggested its clinical efficacy in humans [1] . The mechanism of lipid rescue is thought to be a combination of reduced tissue binding by reestablished equilibrium in a plasma lipid phase and a beneficial energetic-metabolic effect. Ropivacaine may be less responsive to lipid rescue therapy because of its decreased lipophilicity. Slow accumulation into tissues may be more difficult to reverse than a sudden bolus [2] .
We have evidence of ropivacaine toxicity considering the Naranjo algorithm score of 6, which correlates to the category of a probable adverse drug reaction. The pharmacokinetics are not affected by renal failure, and the liver accounts for the majority of clearance [3] . In this patient, the impaired liver was further hypoperfused, considering myocardial depression. This report suggests the failure of lipid rescue.
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